Carlos G. G.
- Country
- Spain
- Department
- Hematology
Research Overview
- Evaluation of Venetoclax Combined With Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Untreated BCL-2 IHC-Positive DLBCL Patients
- Phase 1b Study of Mosunetuzumab and Glofitamab with CC-220 and CC-99282 in B-Cell Non-Hodgkin Lymphoma Patients
- A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, versus Standard of Care Therapy in Participants with Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma (OLYMPIA-4)
Data & Insights
Has run more than one trial at 187 of 348 partner sites.
Specializations
Lymphoma Research
Focused on investigating novel treatments for various forms of B-cell lymphomas, including mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma.
- Non-Hodgkin's Lymphoma Variants
- Marginal Zone Lymphoma
- B-Cell Malignancies
Evaluates innovative therapeutic approaches including targeted therapies and immunotherapeutic agents.
Immunotherapy Development
Specializes in studying advanced immunotherapeutic approaches including cancer vaccines, bispecific antibodies, and CAR-T cell therapy for hematologic malignancies.
- Novel Antibody Treatments
- Cellular Therapy
- Combination Immunotherapy
Investigates immune-based treatments for both newly diagnosed and relapsed/refractory conditions.
Autoimmune Disorders
Conducts research on various autoimmune conditions including immune thrombocytopenia, dermatomyositis, and Behçet's syndrome.
- Complement Pathway Inhibition
- Autoimmune Blood Disorders
- Inflammatory Conditions
Studies novel therapeutic approaches targeting classical complement pathways in immunological diseases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.